Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Chitogenx Inc. (CHGX.CN)

Chitogenx Inc. (CHGX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CHITOGENX ANNOUNCES EXECUTIVE LEADERSHIP CHANGES Newswire.ca - Wed Feb 28, 3:30PM CST

/CNW/ - ChitogenX Inc. (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today announced that Philippe...

CHGX.CN : 0.0400 (-11.11%)
CHNXF : 0.0354 (-29.20%)
CHITOGENX REPORTS THIRD QUARTER 2024 RESULTS Newswire.ca - Wed Jan 3, 6:00AM CST

Launch of new skin repair development program targeting $19B in unmet medical needs Successful demonstration of protection from joint degeneration and...

CHGX.CN : 0.0400 (-11.11%)
CHNXF : 0.0354 (-29.20%)
CHITOGENX DEMONSTRATES ORTHO-R EFFICACY AND OSTEOARTHRITIS PROTECTION IN LARGE ANIMAL MENISCAL REPAIR STUDY Newswire.ca - Thu Nov 9, 2023

/CNW/ - ChitogenX Inc. (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today announced that ORTHO-R,...

CHGX.CN : 0.0400 (-11.11%)
CHNXF : 0.0354 (-29.20%)
CHITOGENX LAUNCHES BURN AND SKIN REPAIR DEVELOPMENT PROGRAM Newswire.ca - Tue Nov 7, 2023

/CNW/ - ChitogenX Inc., (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today announced that it has...

CHGX.CN : 0.0400 (-11.11%)
CHNXF : 0.0354 (-29.20%)
CHITOGENX REPORTS SECOND QUARTER 2024 RESULTS Newswire.ca - Fri Sep 29, 2023

/CNW/ - ChitogenX Inc., (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today reported its financial...

CHGX.CN : 0.0400 (-11.11%)
CHNXF : 0.0354 (-29.20%)
CHITOGENX RECEIVES NOTICE OF ALLOWANCE FOR KEY PATENT IN UNITED STATES AND CANADA Newswire.ca - Thu Sep 28, 2023

/CNW/ - ChitogenX Inc., (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today announced that it has...

CHGX.CN : 0.0400 (-11.11%)
CHNXF : 0.0354 (-29.20%)
CHITOGENX CONCLUDES ENROLMENT FOR ITS U.S. PHASE I/II ROTATOR CUFF TEAR REPAIR CLINICAL TRIAL Newswire.ca - Tue Sep 26, 2023

/CNW/ - ChitogenX Inc., (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today announced that it has...

CHGX.CN : 0.0400 (-11.11%)
CHNXF : 0.0354 (-29.20%)
CHITOGENX ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS Newswire.ca - Wed Aug 2, 2023

/CNW/ - ChitogenX Inc., (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today announced the voting...

CHGX.CN : 0.0400 (-11.11%)
CHNXF : 0.0354 (-29.20%)
CHITOGENX REPORTS FIRST QUARTER 2024 RESULTS Newswire.ca - Fri Jun 30, 2023

Patient recruitment for our Rotator cuff repair Phase I/II trial reached important milestone ORTHO-R soft-tissue residency properties confirmed in...

CHGX.CN : 0.0400 (-11.11%)
CHNXF : 0.0354 (-29.20%)
CHITOGENX RETAINS BRUDER CONSULTING & VENTURE GROUP TO BROADEN AND ACCELERATE ONGOING STRATEGIC DEVELOPMENT PARTNERSHIP DISCUSSIONS Newswire.ca - Thu Jun 15, 2023

/CNW/ - ChitogenX Inc., (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today announced it has...

CHGX.CN : 0.0400 (-11.11%)
CHNXF : 0.0354 (-29.20%)

Barchart Exclusives

Dropbox’s Unusually Active Call Is a Screaming Buy Before Today’s Q1 2024 Results Barchart - 1 hour ago
On Wednesday, Dropbox had an unusually active call option with a Vol/OI ratio of 17.27, putting it in the top 25. The call is a screaming buy, with Q1 2024 results out after today’s close. Here’s why. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot